Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

318
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
318
Tumor Immunotherapy01:27

Tumor Immunotherapy

501
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
501
Hybridoma Technology01:31

Hybridoma Technology

14.4K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.4K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.

American journal of hematology·2026
Same author

Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL.

Blood advances·2026
Same author

Clinical Evaluation of Ex Vivo Expanded MUC1-Specific Peripheral Blood T Cells for Adoptive Immunotherapy in Relapsed/Refractory Multiple Myeloma.

Cancer research communications·2026
Same author

Real-world outcomes of cilta-cel versus BCMA-targeting bispecific antibodies in relapsed/refractory multiple myeloma.

Leukemia & lymphoma·2026
Same author

Mutational Profiling Links Biologically Relevant Variants to Multi-Systemic Rosai-Dorfman Disease.

Blood advances·2026
Same author

Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study.

Blood·2026

相关实验视频

Updated: Jun 19, 2025

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.0K

在多发性骨髓瘤中进行IgG替代.

Alex Wonnaparhown1, Talal Hilal2, Jacqueline Squire3

  • 1Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic, Phoenix, AZ, USA. Wonnaparhown.Alex@mayo.edu.

Blood cancer journal
|July 25, 2024
PubMed
概括
此摘要是机器生成的。

化学抗原受体T细胞疗法和双特异性抗体可以改善多发性骨髓瘤的结果,但会导致低血. 免疫球蛋白G替代疗法对这些患者的感染管理有希望.

更多相关视频

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.8K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.6K

相关实验视频

Last Updated: Jun 19, 2025

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.0K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.8K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.6K

科学领域:

  • 免疫学 免疫学 免疫学
  • 血液学 血液学 血液学
  • 在瘤学瘤学.

背景情况:

  • 包括化学抗原受体 (CAR) T细胞疗法和双特异性抗体 (BiAbs) 在内的T细胞参与剂 (TCE) 已经彻底改变了多发性骨髓瘤 (MM) 治疗.
  • 这些先进疗法与二次免疫缺陷和低血糖球蛋白 (HG) 相关,导致复发性感染.
  • 由于MM患者的寿命更长,管理与治疗相关的感染和发病率至关重要.

研究的目的:

  • 审查多发性骨髓瘤中与TCE相关的感染风险和低血.
  • 讨论目前和潜在的策略,以使用免疫球蛋白G替代疗法 (IgG-RT) 管理TCE后的MM患者的低血糖球蛋白血症.
  • 突出了对IgG-RT在这个患者群体中的标准化方案的需要.

主要方法:

  • 本综述综合了多发性骨髓瘤中TCE的现有文献,重点关注二次性免疫缺陷和低血.
  • 它研究了免疫球蛋白G替代疗法 (IgG-RT) 原则的应用,从原发性免疫缺陷到MM.
  • 该综述讨论了TCE治疗MM患者IgG-RT管理的临床结果,挑战和未来方向.

主要成果:

  • TCE治疗显著改善了多发性骨髓瘤的临床结果,但增加了HG和随后感染的风险.
  • 免疫球蛋白G替代疗法 (IgG-RT) 是一次性免疫缺陷的标准,在治疗TCE后MM患者的高血压和感染方面显示出有前途的结果.
  • 然而,目前缺乏针对接受TCE治疗的MM患者的IgG-RT启动,剂量和监测的具体指南.

结论:

  • 有效地管理二次免疫缺陷和低甘球蛋白血症对于改善多发性骨髓瘤患者的长期治疗结果至关重要.
  • 为了获得最佳的患者护理,需要对免疫球蛋白G替代疗法 (IgG-RT) 协议进行进一步的研究和标准化.
  • 多发性骨髓瘤治疗的未来进展将涉及更好地识别免疫缺陷,风险分层和综合管理策略,包括IgG-RT.